• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by ProMIS Neurosciences Inc.

    4/9/26 4:02:22 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    DEFA14A 1 pmn-20260409xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14 (a) of the

    Securities Exchange Act of 1934 (Amendment No.  )

    ​

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    PROMIS NEUROSCIENCES INC.

    (Name of Registrant as Specified in its Charter)

    Not applicable.

    (Name of Person (s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and 0-11.


    GRAPHIC

    *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V92333-P49784 PROMIS NEUROSCIENCES INC. ONE BROADWAY, SUITE 1400 CAMBRIDGE, MA 02142 USA Your Vote Counts! PROMIS NEUROSCIENCES INC. 2026 Annual Meeting Vote by May 19, 2026 11:59 PM ET Vote Virtually at the Meeting* May 20, 2026 10:30 am, Eastern Time Virtually at: www.virtualshareholdermeeting.com/PMN2026 You invested in PROMIS NEUROSCIENCES INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 20, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 6, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V92334-P49784 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors To elect seven directors, each to serve until the next annual meeting of shareholders and until his or her respective successors is duly elected and qualified, or such director’s earlier death, resignation, or removal. 1a. Eugene Williams For 1b. Neil Cashman, M.D. For 1c. Joshua Mandel-Brehm For 1d. Maggie Shafmaster, Ph.D., J.D. For 1e. Neil K. Warma For 1f. William Wyman For 1g. Slanix Alex, Pharm.D For 2. Appointment of Auditors To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve an amendment to the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $PMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/6/26 7:28:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/4/26 6:08:32 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaplan Johanne bought $25,005 worth of shares (1,629 units at $15.35), increasing direct ownership by 70% to 3,941 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/23/26 8:31:05 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/6/26 7:28:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/4/26 6:08:32 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Abg V-Siv Ix Ltd claimed ownership of 943,090 shares (SEC Form 3)

    3 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/25/26 7:30:29 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

    Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark. The posters will highlight ongoing research related to the Company's proprietary discovery platform and its approach to selectively targeting toxic misfolded proteins in neurodegenerative diseases. Oral Platform Presentation Details Presentation #1Title: Rati

    3/18/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY. The fireside chat will be held at 9:30am Eastern Time on Wednesday, February 11th and a live webcast of the presentation may be accessed by visiting the Events page of the Company's website at www.promisneurosciences.com. The webcast

    2/4/26 4:05:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    SEC Filings

    View All

    SEC Form DEFA14A filed by ProMIS Neurosciences Inc.

    DEFA14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

    4/9/26 4:02:22 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by ProMIS Neurosciences Inc.

    DEF 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

    4/9/26 4:01:19 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.

    SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    4/7/26 4:27:01 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Financials

    Live finance-specific insights

    View All

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    View All

    ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

    Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, has joined the Company's Board of Directors. Dr. Alex has a highly distinguished Wall Street career spanning multiple leadership positions at public market

    10/22/25 7:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

    5/14/24 4:01:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

    4/1/24 4:15:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 3:36:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/6/24 4:15:57 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care